Adverum Biotechnologies Inc (NASDAQ:ADVM) stock price target raised to $5.00, reported today by Zacks Investment Research
- Updated: September 16, 2016
Just yesterday Adverum Biotechnologies Inc (NASDAQ:ADVM) traded 0.80% higher at $4.24. Adverum Biotechnologies Inc’s 50-day moving average is $4.02 and its two hundred day moving average is $4.33. The last stock price is down 12.40% relative to the two hundred day average, compared with the S&P 500 Index which has fallen -0.01% over the date range. Volume of trade was was down over the average, with 159,399 shares of ADVM changing hands under the typical 289,588 shares..
Zacks Investment Research upped the price target of Adverum Biotechnologies Inc (NASDAQ:ADVM) to $5, indicating a possible upside of 0.18%,
Previously on 6/08/2016, Chardan Capital released a statement on Adverum Biotechnologies Inc(NASDAQ:ADVM) dropped the target price from $7.50 to $5.00 that indicated a possible upside of 0.11%.
Recent Performance Chart:
A total of 3 equity analysts have reported on the stock. One analyst rate the company a strong buy, two firms rate the stock a buy, 0 firms rate the company a hold, 0 rate the company to underperform, and lastly 0 analystsrate the company as sell with an average target price of $9.50
With a market cap of $0.0, Adverum Biotechnologies Inc has a PE of 0 with a 52 week low of $2.99 and a one-year high of $11.46.
Brief Synopsis About Adverum Biotechnologies Inc (NASDAQ:ADVM)
Adverum Biotechnologies, Inc., formerly Avalanche Biotechnologies, Inc., is a gene therapy company. The Company is engaged in discovering and developing medicines to patients suffering from chronic or debilitating disease. The Company operates and manages its business in the segment of developing and commercializing gene therapeutics. It focuses on diseases with unmet medical need, including ophthalmic diseases, such as wet age-related macular degeneration (AMD), as well as rare genetic diseases. The Company’s product candidates include AVA-101 and AVA-201 for treatment of Wet AMD; AVA-322 and AVA-323 for the treatment of Color Vision Deficiency, and and AVA-311 for the treatment of Juvenile X-linked Retinoschisis. It has generated human proof-of-concept data for AVA-101 in a Phase I trial with over eight wet AMD subjects conducted at Lions Eye Institute (LEI) in Australia. It is developing AVA-322 and AVA-323 for the treatment of color vision deficiency (CVD).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.